News - BioSpace
BioSpace is the digital hub for life science news and jobs.We provide essential insights, opportunities and tools to connect innovative organizations and talented professionals who advance health and quality of life across the globe.
BioSpace: Biotech, Pharmaceutical and Clinical Research News
Dec 11, 2010 · GSK, Gilead and Arcellx, Vertex and more present new data at the American Society of Hematology annual meeting just as sickle cell therapies Casgevy and Lyfgenia have a new outcomes-based payment model; Eli Lilly and Novo Nordisk pump new funds into manufacturing; and AbbVie makes a Cerevel comeback while uniQure clears a path toward accelerated approval in Huntington’s disease.
Join Our Team - BioSpace
BioSpace is the digital hub for life sciences news and jobs. Our mission is to provide essential insights, tools, and opportunities to connect the innovative organizations and talented professionals who advance health and quality of life across the globe.
Ring Therapeutics Lets Go of Nearly Half Its Staff - BioSpace
6 days ago · June 27. EuroAPI, a spinoff of Sanofi, will lay off approximately 550 people by 2027, the company announced Wednesday. The cuts are part of a multi-year restructuring plan that EuroAPI first made public when it unveiled its 2023 results, though few details were given at the time.According to the Wednesday announcement, the manufacturer will sell plants in Haverhill, UK, and Brindisi, Italy ...
PTC Wins First FDA Nod for Direct-to-Brain Gene Therapy, Targets ...
Nov 14, 2024 · The FDA on Wednesday signed off on PTC Therapeutics’ gene therapy eladocagene exuparvovec-tneq for the treatment of aromatic L-amino acid decarboxylase deficiency. The treatment will be marketed under the brand name Kebilidi. With only around 350 cases reported in the literature, aromatic L-amino acid decarboxylase (AADC) deficiency is an ultrarare genetic disease characterized by severe ...
ESSENCE Phase 3 trial results demonstrating statistically
The trial achieved both its primary endpoints, with semaglutide 2.4 mg demonstrating statistically significant and superior improvements in liver fibrosis with no worsening of steatohepatitis, as well as resolution of steatohepatitis with no worsening of liver fibrosis in people with MASH compared to placebo. 1 Supportive secondary endpoints showed …
Neurogene Drops Batten Gene Therapy Program - BioSpace
Nov 19, 2024 · In addition to a Monday morning announcement of a complication for its Rett syndrome gene therapy, Neurogene has dropped another doozy on investors in stopping its gene therapy program for Batten disease.. In its third quarter earnings release and a prior press release on Nov. 11, Neurogene stated that while it had completed enrollment for the NGN-101 Phase I/II trial, it does not expect to ...
With Myriad Recent Approvals in Cancer, The Era of ... - BioSpace
Oct 14, 2024 · With Merck’s mega-blockbuster monoclonal antibody Keytruda set to lose exclusivity in 2028, another class of immunotherapy is waiting in the wings to take center stage in cancer treatment: bispecific antibodies with two separate targets.
Big Pharma’s Interest Grows in Evolving Cell and Gene ... - BioSpace
Oct 9, 2024 · In welcome remarks at the conference on Monday, Alliance for Regenerative Medicine (ARM) CEO Tim Hunt said there has been uptick in investment in cell and gene therapies in 2024, noting that 13 of the 15 largest pharma companies by market capitalization have an “active presence” in the sector.. Hunt said many leading Big Pharma companies—including Astellas, Bayer, BMS, Eli Lilly, Gilead ...
All News - BioSpace
5 days ago · In 2023, the FDA greenlit 55 new drugs and 34 cell and gene therapies. Follow along as BioSpace keeps you up to date on all of the FDA’s decisions in 2024.